February 8, 2022 5:12pm
Another Abbott and Costello rendering fits with this a.m.’s post although weak
Pre-open Indications: 6 Hits, 2 Miss and 1 Pump/Promoted
If I have learned one thing as a former research analyst, venture and public fund investor now a journalist; it is that your life and your bank account are largely tied to your knowledge of price movements and questioning pricing targets.
Who else is tracking a broad grouping of cell and gene therapy equities – with facts supported by real numbers?
The Dow closed UP +371.65 points (+1.06%); the S&P closed UP +37.67 points (+0.84%) while the Nasdaq closed UP +178.79 points (+1.28%)
Henry’omics:
Macros matter …
U.S. stock indexes were higher on Tuesday in choppy dealings as Europe slipped while the euro was pegged back as the European Central Bank tried to cool interest rate hike expectations.
Wall Street is on edge watching how the Federal Reserve will react to the intensifying price pressures, with many investors eyeing Thursday’s consumer price index data release as a key event for markets this week. The inflation data is expected to show that prices rose 0.4% in January, for a 7.2% gain from one year ago, which would be the highest in almost 40 years. <CNBC>
Note: Pfizer Inc. (PFE -$1.51 or -2.84% to $51.70) fell after projecting $54 billion in full-year sales of its COVID-19 vaccine and antiviral pill, a miss on ambitious estimates. Despite raising its forecast for the vaccine by $1 billion to $32 billion, the drugmaker warned that it does not expect final sales for the year to top significantly that figure. "There is less potential upside to this guidance through the year, compared to the situation we faced in 2021 when the vaccine was newly available and few people had received any doses of the vaccine," Chief Financial Officer Frank D’Amelio said in post-earnings remarks. Pfizer was down 5.82% to $50.12 per share as of 10:21 a.m. ET. <Yahoo! Finance>
RegMed Investors’ (RMi) pre-open: “who’s up, what’s going to happen, which names and when? Not quite Abbot & Costello but, the algorithms are warming-up to pitch” … https://www.regmedinvestors.com/articles/12291
RegMed/Stem/Cell and Gene therapy’s 35 covered equities’ Advance/Decline (A/D) lines: what happened …
- Tuesday opened negative at 16 up/17 downs, 1 flat and 1 acquired, slipped further negative at the mid-day at 10/24 and 1 acquired, ending with a negative close of 14/19, 1 flat and 1 acquired;
- Monday opened positive at 33 up/1 downs and 1 acquired, stayed positive at the mid-day at 30/4, 1 flat and 1 acquired, ending with a positive close of 29/4, 1 flat and 1 acquired;
Pre-open indications: 6 Hits <Alnylam Pharmaceuticals (ALNY -$1.01), Editas Medicine (EDIT +$1.88), Ionis Pharmaceuticals (IONS +$0.22), Intellia Therapeutics (NTLA -$4.18), Sage Therapeutics (SAGE +$0.25), Applied Genetic Technologies (AGTC +$0.17)> 2 MISS < CRISPR Therapeutics (CRSP -$1.32), Brainstorm Cell Therapeutics (BCLI -$0.09)> 1 PIMP/PUMP/PROMOTE <Biostage (BSTG +$0.05)>
The Biostage (BSTG) Chronicles: shows how the “pimp/pump and promote” works with the shares trading up +$0.05 with 1,293 shares traded after Monday’s +$0.55 with 2,311 shares traded, Friday’s +$0.22 with 305 shares traded, Thursday’s flat ($0.00) with 3 shares traded, Wednesday’s down -$0.53 with 502 shares traded, Tuesday’s +$0.40 with 1,088 shares after Monday’s 11 shares traded after Friday’s +$0.05 with 3,225 shares traded after Thursday’s +$0.24 with 10,073 - double the mornings 5,030 shares traded after last Wednesday’s diving to -$0.00 with 7,796 shares trading after appreciating +$0.35 (after dropping mid-day -$0.07 – such sarcasm after miraculous jump) and the previous Tuesday’s +$0.31 with 2,794 shares traded.
Key Metrics:
- Tuesday - Sector volume was LOW with 2 of the 14-upside having higher than the 3-month average volume with LOW volume of 5 of 19-downside having higher than the 3-month average volume
- Monday - Sector volume was LOW with 4 of the 29-upside having higher than the 3-month average volume with LOW volume of 1 of 4-downside having higher than the 3-month average volume;
The iShares NASDAQ Biotechnology (IBB) and the SPDR S&P ETF (XBI) indicators:
- Tuesday the IBB closed down -0.07% and XBI closed down -0.33%
- Monday the IBB closed up +0.77% and XBI closed up +2.71%
The CBOE Volatility Index (VVIX: INDEX) tracked:
- Tuesday was down -1.31 points or -5.86 at 21.52
- Monday was down -0.34 points or -1.46% at 22.88
Jumping with share pricing momentum (10 of 14):
- ReNeuron (RENE.L +$0.80 after Monday’s -$1.00),
- AxoGen (AXGN +$0.40),
- Regenxbio (RGNX +$0.39 after Monday’s +$0.73),
- Sage Therapeutics (SAGE +$0.25 after Monday’s +$1.88),
- Global Blood Therapeutics (GBT +$0.24 after Monday’s +$1.21),
- Ionis Pharmaceuticals (IONS +$0.22 after Monday’s +$0.96),
- Applied Genetic Technologies (AGTC +$0.17),
- Mesoblast (MESO +$0.08),
- Biostage (BSTG +$0.05),
- MiMedx (MDXG +$0.03),
Hammered in today’s market (10 of 29):
- Intellia Therapeutics (NTLA +$1.47 after Friday’s +$1.43),
- Editas Medicine (EDIT +$0.59 after Friday’s +$0.76),
- CRISPR Therapeutic (CRSP -$
- Alnylam Pharmaceuticals (ALNY +$3.23 after Friday’s +$2.91),
- Ultragenyx (RARE +$1.17 after Friday’s +$1.01),
- Cellectis SA (CLLS -$0.22),
- Homology Medicine (FIXX -$0.16),
- uniQure NV (QURE -$0.14),
- Fate Therapeutics (FATE +$0.76 after Friday’s +$1.07),
- Bluebird bio (BLUE -$0.11),
Closing Flat:
- 1 – Adverum Biotechnologies (ADVM) – 1- Stemline Therapeutics (STML) – acquired
February, Q1/2022:
- Tuesday closed negative with 14 incliners, 19 decliners, 1 flat and 1 acquired
- Monday (2/7) closed positive with 29 incliners, 4 decliners, 1 flat and 1 acquired
The BOTTOM LINE: The sector feels the pain again as share pricings slipped as I had stated “the algorithms are warming-up to pitch” in the a.m. post.
Some of the most equities that were leading in Monday’s trading were trampled in Tuesday’s session.
Tuesday’s ReNeuron (RENE.L) raced to the upside after feeling the grit of laying in the dirt of the downside while: up again were Alnylam Pharmaceuticals (ALNY), Sage Therapeutics (SAGE and Global Blood Therapeutics (GBT) while the few down-trodden were Intellia therapeutics (NTLA) after yesterday’s up and Editas Medicine (EDIT) and CRISPR Therapeutics (CRSP), along with yesterday’s losers BioLife Solutions (BLFS) and Precigen (PGEN).
Investors will be watching earnings reports this week; Q4 and end-of-year earnings are about to be made aware of” more than even I thought.
• Ultragenyx Pharmaceuticals (RARE) - 2/10, Thursday
• Alnylam Pharmaceuticals (ALNY) reports Q4 and FY21 on Thursday, 2/10
• Applied Genetic Technologies (AGTC) on Monday, 2/14
• AxoGen AXGN) – 2/22, Tuesday
Algorithms, hedge funds and traders continue to punish and … then push the cell and gene therapy stocks as valuations “creep” up.
WHY do I keep analyzing Biostage (BSTG): I WAS there to experience the lack of investor prerogatives and saw the decay of transparency and more; it takes courage, resolve and patience to stay the course of asking the questions without response!
Who is defining the metrics for investors and keeping you notified of the sector and market fluctuations? What I provide is a trusted source of share pricing intelligence – it’s more than opinion, I deal in the facts and numbers that back them up.
Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice.
Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors. All investments are subject to risks. Investors should consider investment objectives.
Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.
Regulation Analyst Certification (Reg AC): The research analyst primarily responsible for the content of this report certifies the following under Reg AC: I hereby certify that all views expressed in this report accurately reflect my personal views about the subject company or companies and its or their securities. I also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report.
